$SSII
SS Innovations International, Inc. Stock $ssii

$ssii Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039573 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$1.575M
YoY Change
Cost Of Revenue	$1.351M	$1.000M	$28.24K
YoY Change	1930.88%	3441.78%	-87.14%
Gross Profit	$224.2K	$511.2K	-$28.24K
YoY Change	-436.94%	-1910.13%	-87.14%
Gross Profit Margin	14.23%
Selling, General & Admin	$1.983M	$1.417M	$52.22K
YoY Change	1815.99%	2613.44%	-35.11%
% of Gross Profit	884.64%	277.19%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$308.6K	$2.280K	$2.310K
YoY Change	13435.96%	-1.3%	-68.53%
% of Gross Profit	137.68%	0.45%
Operating Expenses	$1.983M	$2.057M	$80.46K
YoY Change	1066.3%	2456.76%	-73.19%
Operating Profit	-$1.759M	-$1.546M	-$108.7K
YoY Change	643.53%	1322.21%	-79.08%
Interest Expense	-$91.53K	$67.70K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$91.53K	$52.75K	$35.00
YoY Change	-315731.03%	150605.71%	59.09%
Pretax Income	-$1.850M	-$2.004M	-$80.42K
YoY Change	988.48%	2392.28%	-73.2%
Income Tax
% Of Pretax Income
Net Earnings	-$1.850M	-$2.004M	-$80.42K
YoY Change	988.48%	2392.28%	-73.2%
Net Earnings / Revenue	-117.46%
Basic Earnings Per Share	$0.00	-$0.03	$0.00
Diluted Earnings Per Share	$0.00	-$0.03	$0.00
COMMON SHARES
Basic Shares Outstanding	146.2M shares	53.89M shares	37.85M shares
Diluted Shares Outstanding		61.71M shares	37.85M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$423.1K	$448.5K	$346.9K
YoY Change	62.04%	29.31%	9.49%
Cash & Equivalents	$423.1K	$448.5K	$346.9K
Short-Term Investments
Other Short-Term Assets	$1.383M	$8.680K	$2.290K
YoY Change	60309.17%	279.04%	0.0%
Inventory	$2.608M
Prepaid Expenses
Receivables	$1.070M
Other Receivables	$0.00
Total Short-Term Assets	$5.485M	$5.457M	$349.2K
YoY Change	1982.66%	1462.96%	9.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$436.5K	$9.120K	$18.24K
YoY Change	2635.53%	-49.99%	-42.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$4.208M	$9.120K	$18.24K
YoY Change	26271.21%	-49.99%	-87.64%
TOTAL ASSETS
Total Short-Term Assets	$5.485M	$5.457M	$349.2K
Total Long-Term Assets	$4.208M	$9.120K	$18.24K
Total Assets	$9.693M	$5.466M	$367.4K
YoY Change	3370.13%	1387.86%	-21.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$31.76K		$114.1K
YoY Change	-43.17%		10.26%
Accrued Expenses	$2.131M	$5.700K	$19.20K
YoY Change	10193.86%	-70.31%	-97.93%
Deferred Revenue
YoY Change
Short-Term Debt	$6.188M	$5.000M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.372M	$5.119M	$278.3K
YoY Change	3678.11%	1739.69%	-77.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$500.0K		$0.00
YoY Change
Total Long-Term Liabilities	$500.0K	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.372M	$5.119M	$278.3K
Total Long-Term Liabilities	$500.0K	$0.00	$0.00
Total Liabilities	$8.872M	$5.119M	$278.3K
YoY Change	3903.85%	1739.69%	-77.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.10M	-$12.70M	-$8.558M
YoY Change	118.85%	48.34%	17.34%
Common Stock	$14.62K	$6.544K	$3.785K
YoY Change	283.7%	72.89%	-99.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$26.00K
YoY Change
Treasury Stock Shares
Shareholders Equity	$821.6K	$347.4K	$89.15K
YoY Change
Total Liabilities & Shareholders Equity	$9.693M	$5.466M	$367.4K
YoY Change	3370.13%	1387.86%	-21.27%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.850M	-$2.004M	-$80.42K
YoY Change	988.48%	2392.28%	-73.2%
Depreciation, Depletion And Amortization	$308.6K	$2.280K	$2.310K
YoY Change	13435.96%	-1.3%	-68.53%
Cash From Operating Activities	-$10.34M	-$336.6K	-$58.91K
YoY Change	6451.67%	471.51%	-25.34%
INVESTING ACTIVITIES
Capital Expenditures	$736.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$1.228M	-$2.000M	$0.00
YoY Change
Cash From Investing Activities	$492.5K	-$2.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.825M	$1.434M
YoY Change	13530.04%
NET CHANGE
Cash From Operating Activities	-10.34M	-$336.6K	-$58.91K
Cash From Investing Activities	492.5K	-$2.000M
Cash From Financing Activities	9.825M	$1.434M
Net Change In Cash	-25.49K	-$902.8K	-$58.91K
YoY Change	-70.28%	1432.67%	-137.73%
FREE CASH FLOW
Cash From Operating Activities	-$10.34M	-$336.6K	-$58.91K
Capital Expenditures	$736.0K
Free Cash Flow	-$11.08M	-$336.6K	-$58.91K
YoY Change		471.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	333-216054
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3478854
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1500 SE 15th Street,
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	#512,
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Lauderdale,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33316
CY2023Q1	dei	City Area Code CityAreaCode	(954)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	478-1410
CY2023Q1	dei	Security12b Title Security12bTitle	None
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	146172439	shares
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	448543	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1351364	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8678	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8678	usd
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	5000000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3000000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	5457221	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4360042	usd
CY2023Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	98592	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	98592	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	89472	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	87193	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9120	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11399	usd
CY2023Q1	us-gaap	Assets Assets	5466341	usd
CY2022Q4	us-gaap	Assets Assets	4371441	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5700	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5700	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	113227	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	45529	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	5000000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4000000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5118927	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4051229	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65443337	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65443337	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53887738	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53887738	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	6544	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5389	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	13036260	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11005895	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12695391	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10691071	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	347414	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	320213	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5466341	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4371441	usd
CY2023Q1	avmr	Compensation Expense CompensationExpense	1592309	usd
CY2022Q1	avmr	Compensation Expense CompensationExpense	28240	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	464758	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	52215	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2057067	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	80455	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	46	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	35	usd
CY2023Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	120000	usd
CY2023Q1	us-gaap	Other Income OtherIncome	400	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	67699	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	52747	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2004320	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-80421	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2004320	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-80421	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.032
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.002
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61705851	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37849405	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	320213	usd
CY2023Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	1597693	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	432672	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1156	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2004320	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	347414	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	141326	usd
CY2022Q1	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	27476	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	764	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-80421	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	89145	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2004320	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-80421	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2279	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2305	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1597693	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	28240	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	67699	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9030	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-336649	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58905	usd
CY2023Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	2000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2000000	usd
CY2023Q1	avmr	Proceeds From Securities Offering ProceedsFromSecuritiesOffering	446188	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	12360	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.07	pure
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1433828	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-902821	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-58905	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1351364	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	405774	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	448543	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	346869	usd
CY2022Q1	us-gaap	Interest Paid InterestPaid	35	usd
CY2023Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	347414	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2023, $198,543 were in excess of the FDIC insured limit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1	avmr	Fdic Insured FDICInsured	250000	usd
CY2023Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	198543	usd
CY2023Q1	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1175000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2021	avmr	Warrants Per Value WarrantsPerValue	0.78
CY2021	avmr	Stock Compensation Expenses StockCompensationExpenses	912489	usd
CY2022	avmr	Stock Compensation Expenses StockCompensationExpenses	0	usd
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	135808884	shares
CY2023Q1	avmr	Common Stock Ownership Percentage CommonStockOwnershipPercentage	0.95	pure
CY2023Q1	avmr	Exercise Percentage exercisePercentage	0.51	pure
CY2023Q1	avmr	Merger Agreement Description MergerAgreementDescription	the Company issued 14,029,170 post-Merger shares of SSII common stock to Dr. Frederic Moll and one other accredited investor, who each provided $3,000,000 in interim financing to the Company pending consummation of the Merger. Pursuant to his investment agreement with the Company, dated April 7, 2023, which included his $3,000,000 investment, and which was described in and included as an Exhibit to the Company’s Report on Form 8-K, dated April 14, 2023, Dr. Moll received 7% of SSI’s post-merger issued and outstanding common stock on a fully diluted basis or an aggregate of 10,149,232 SSI Shares
CY2023Q1	avmr	Royalty Percentage RoyaltyPercentage	0.03	pure
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one for ten Reverse Stock Split
CY2023Q1	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	250000000	shares
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	SS Innovations International, Inc.
CY2023Q1	dei	Trading Symbol TradingSymbol	AVMR
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NONE
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	8066176	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	670000	shares
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	189500	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	600000	shares
CY2023Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	240000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	6600	shares
CY2023Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2019-07-31
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1829.25	usd
CY2019Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	2454.75	usd
CY2019Q3	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2223	usd
CY2021Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1474.17	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Revenues Revenues		usd
CY2022Q1	us-gaap	Revenues Revenues		usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2022Q1	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.002
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37849405	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61705851	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	avmr	Proceeds From Securities Offering ProceedsFromSecuritiesOffering		usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid InterestPaid		usd
CY2023Q1	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock		usd
CY2022Q1	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock		usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q1	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q1	avmr	Reduction Of Account Payable And Equipment ReductionOfAccountPayableAndEquipment		usd
CY2022Q1	avmr	Reduction Of Account Payable And Equipment ReductionOfAccountPayableAndEquipment		usd
CY2022Q3	avmr	Raising Amount RaisingAmount	3225156	usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001676163

Files In Submission

Name	View Source	Status
0001213900-23-039573-index-headers.html	Edgar Link	pending
0001213900-23-039573-index.html	Edgar Link	pending
0001213900-23-039573.txt	Edgar Link	pending
0001213900-23-039573-xbrl.zip	Edgar Link	pending
avmr-20230331.xsd	Edgar Link	pending
avmr-20230331_cal.xml	Edgar Link	unprocessable
avmr-20230331_def.xml	Edgar Link	unprocessable
avmr-20230331_lab.xml	Edgar Link	unprocessable
avmr-20230331_pre.xml	Edgar Link	unprocessable
f10q0323ex31-1_ssinnova.htm	Edgar Link	pending
f10q0323ex31-2_ssinnova.htm	Edgar Link	pending
f10q0323ex32-1_ssinnova.htm	Edgar Link	pending
f10q0323ex32-2_ssinnova.htm	Edgar Link	pending
f10q0323_ssinnovations.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0323_ssinnovations_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSII
SS Innovations International, Inc. Stock $ssii

2023 Q2 Form 10-Q Financial Statement

#000121390023039573 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII SS Innovations International, Inc. Stock $ssii

2023 Q2 Form 10-Q Financial Statement

#000121390023039573 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII
SS Innovations International, Inc. Stock $ssii